Some reports have suggested that AML cells with the FLT3-ITD mutation are more sensitive to sorafenib [8, 21]; however, a recent study has shown that FLT3 wild-type cell lines can exhibit different sensitivities to this drug [22]. This evidence concerns the gene FLT3 and acute myeloid leukemia.